The experimental drug, fosgonimeton, failed to reach statistical significance in a test that measures cognition and other functions, compared to placebo at 26 weeks. "These are not the results we ...
Shares tumble 12%, to $16.18, in post-market trading. Athira Pharma's trial of fosgonimeton for Alzheimer's disease patients failed to meet its primary endpoint. The biopharmaceutical company said ...
In cases where picking at your nose damages internal tissues, critical species of bacteria have a clearer path to the brain, which responds to their presence in ways that resemble signs of Alzheimer's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results